Abstract 81P
Background
Lenvatinib (LNV) represents a first-line therapeutic agent for the treatment of patients with advanced hepatocellular carcinoma (HCC). The efficacy of LNV in the targeted therapy of numerous cancer types has been demonstrated; however, a significant proportion of patients do not receive long-term benefit due to primary and acquired drug resistance. In this work we aimed to identify molecular pathways involved in acquired resistance to lenvatinib in different HCC models.
Methods
For this study, different models of HCC were used: (1) resistant cell lines, (2) resistant patients PBMCs and (3) co-culture model. Huh-7, SNU449 and HepG2 cell lines were characterised using western blot (WB), colony formation and migration assay. LNV-resistant cell lines (Huh-7/LR and SNU449/LR) were established by increasing doses of LNV (1 to 40 μM). Mechanisms of resistance were explored, and MTT assays were conducted to determine IC50 and cross-resistance acquisition in LR cells to other TKIs. Validation study in co-culture of the HCC-LR cell line and LR-patient-derived PBMC were performed.
Results
WB, migration and colony formation assay of the HCC cell lines enabled the characterisation of the cell lines together with the evaluation of EMT markers. Huh-7 and SNU449, showing a high mesenchymal phenotype and a higher IC50 value than HepG2, were exposed to LNV to induce resistance. SNU449/LR showed the highest levels of p-AKT compared to parental cell lines, together with an increase of the EMT phenotype, i.e. a decrease in E-cadherin and an increase in vimentin and snail, as compared to Huh7-LR. Similarly, an increase in p-EGFR and EGFR was observed in SNU449/LR, while a decrease was seen in Huh-7/LR. Interestingly, LR-cell lines showed sensitivity to Cabozantinib treatment compared to Sorafenib. Further experiments with PBMCs from LR-patients are ongoing to validate findings and explore cross-sensitivity to TKIs alone or in combination with immunotherapy (IO).
Conclusions
Our findings indicate that Cabozantinib is the most effective TKI in LR-cells. Co-culture models of LR-HCC cells and LR-patient-derived PBMCs represent a useful tool to test the cross-resistance ex vivo for TKI combined with IO.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
132P - Deciphering aggressive behavior in uterine inflammatory myofibroblastic tumors: Clinicopathological and molecular analysis
Presenter: Nikola Hajkova
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Exploring genomic instability at the single-cell level using a new method for the inference of copy number alterations
Presenter: Lucrezia Patruno
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - SPICE: Probabilistic reconstruction of copy-number evolution in cancer
Presenter: Abigail Bunkum
Session: Cocktail & Poster Display session
Resources:
Abstract
135P - Revealing the third kind of pathway of colorectal cancer developing from laterally spreading tumors
Presenter: Jianshe Yang
Session: Cocktail & Poster Display session
Resources:
Abstract
136P - Investigating the evolutionary and regulatory dynamics of acquired resistance to BTK inhibitors in activated B-cell diffuse large B-cell lymphoma cells
Presenter: Luminita Ruje
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - PHANTOM: Bootstrap inference of single-cell tumour phylogenies by integrating sequencing read counts
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Analysis of master regulatory transcription factors and their associated transcriptomic profiles in SCLC patients
Presenter: Janik Riese
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Rewiring of cis-regulatory and kinase signalling networks in acalabrutinib-resistant ABC DLBCL cells
Presenter: Pavel Artemov
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - MYC subgroups delineate specific transcriptomic landscape and shape response to radiotherapy in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - An unconditionally dynamic culture system for cancer stem cell
Presenter: Ya-Juan Zhu
Session: Cocktail & Poster Display session
Resources:
Abstract